Barinthus Biotherapeutics
BRNS
BRNS was delisted on the 8th of September, 2026.
13 hedge funds and large institutions have $27.5M invested in Barinthus Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
15% more capital invested
Capital invested by funds: $23.8M → $27.5M (+$3.69M)
8% more funds holding
Funds holding: 12 → 13 (+1)
4.48% more ownership
Funds ownership: 12.44% → 16.93% (+4.5%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HH
HSG Holding
Na,
Hong Kong
|
+$6.84M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.29M |
| 3 |
Morgan Stanley
New York
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$59.7K |
| 2 |
Millennium Management
New York
|
-$35K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.2K |
| 4 |
JP Morgan Chase
New York
|
-$53 |
BRNS Hedge Fund Activity: Q2 2022 in Review
13 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q2 2022, worth a combined $27.5M — up 15% from $23.8M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BRNS positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was HSG Holding, opening a new position worth an estimated $6.84M. The largest seller was Ipswich Investment Management, cutting an estimated $59.7K.
- 13 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q2 2022, up from 12 in Q1 2022.
- Funds reported $27.5M of Barinthus Biotherapeutics stock for Q2 2022, up 15% quarter-over-quarter.
- 2 funds opened new Barinthus Biotherapeutics positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest Barinthus Biotherapeutics buyer in Q2 2022 was HSG Holding, an estimated $6.84M added.
- The largest Barinthus Biotherapeutics seller in Q2 2022 was Ipswich Investment Management, an estimated $59.7K sold.
Based on aggregated 13F filings for Q2 2022.